Rubicon Medical Initiates Second European Clinical Study with the Rubicon Filter; First Human Carotid Artery Cases Successfully Completed in Germany.

Business Editors/Health/Medical Writers

SALT LAKE CITY & HAMBURG, Germany--(BUSINESS WIRE)--Oct. 22, 2003

Rubicon Medical Corp. (OTCBB:RMDC), a Salt Lake City-based developer and manufacturer of medical devices and products, today announced it has successfully completed the first human cases of its Rubicon Filter in the carotid arteries.

Rubicon's carotid studies are being conducted by Prof. Dr. Juachim Schofer, co-founder of the Center of Cardiology and Vascular Intervention in Hamburg, Germany and Rubicon's principal investigator for its clinical studies seeking clearance for use of the Rubicon Filter in carotid arteries.

"The Rubicon Filter performed superbly in the three initial carotid cases performed here in Hamburg. We were particularly impressed with the filter's small profile, ease of use and simple retrieval mechanism," Schofer said. "It is my opinion that the Rubicon Filter will play a key role in the field of embolic protection devices because of its unique features. Those features that will benefit patients undergoing carotid artery stenting."

The carotid arteries are found in the neck and feed blood directly to the brain. Carotid artery stenting is often performed on carotid arteries that have developed blockages as a result of plaque buildup on the artery walls. A stenting procedure involves deploying a small wire mesh tube known as a stent inside a partially blocked blood vessel to improve blood flow by propping open the blood vessel. Helping physicians prevent embolic events from occurring during and after carotid stenting is critical to maintaining blood flow through arteries in the brain and ensuring patient health.

The Rubicon Filter is designed for use in medical procedures downstream from a blockage in a bloodstream to allow the capture and removal of dislodged embolic material. It is a guidewire-based filter that is deployed without the use of a catheter, making it smaller and easier to navigate through blood vessels than other embolic protection devices. Rubicon believes the Rubicon Filter is the world's smallest-profile embolic filtration device. Rubicon also believes the filter's small profile should considerably decrease trauma to the body and the risk of dislodging particles during passage of the filter through a blockage in a blood vessel.

"First, we are honored to be working with Professor Schofer and Dr. Tubler, as well as with the cath lab personnel in Hamburg at one of the leading carotid centers in Germany," said Richard Linder, president and chief executive officer of Rubicon Medical. "We are further grateful to Professor Shofer for his work as the principal investigator of the RULE-Carotid, Europe study using the Rubicon Filter in carotid artery stenting. We are also thrilled with the initial successful results of the Rubicon Filter in this indication and look forward to completing the carotid study in the coming months.

"Additionally, with each new procedure, we grow more and more confident that the Rubicon Filter will revolutionize the field of embolic protection. We also see a growing number of potential applications for our technology."

Rubicon anticipates enrolling additional carotid patients for ongoing trials of the Rubicon Filter in Germany and Italy.

About Rubicon Medical

Rubicon Medical Corporation (www.rubiconmed.com) is a Salt Lake City-based developer and manufacturer of interventional vascular medical devices and products. The company focuses on minimally invasive endovascular techniques and products that are safer and more cost effective than surgery.

Forward Looking Statements: All forward-looking statements in this release are based upon information available to the company on the date of this release. Any forward-looking statements involve risks and uncertainties, including those risks and uncertainties described in the company's filings with the Securities and Exchange Commission, that could cause actual events or results to differ materially from the events or results described in the forward-looking statements, whether as a result of new information, future events or otherwise. Rubicon's Rubicon Filter has not yet been approved for sale in the U.S. or Europe, and no assurance exists that such approvals will be obtained. Readers should not place undue reliance on these forward-looking statements.